Ken Griffin Xeris Biopharma Holdings, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 88,500 shares of XERS stock, worth $253,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,500
Previous 65,700
34.7%
Holding current value
$253,995
Previous $145,000
37.24%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
133Shares Held
57MCall Options Held
126KPut Options Held
45K-
Black Rock Inc. New York, NY10.3MShares$29.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.66MShares$22 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$14.7 Million61.49% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.83MShares$13.9 Million1.75% of portfolio
-
State Street Corp Boston, MA3.26MShares$9.35 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $390M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...